# Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation

> **NCT02161237** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 73 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Advagraf®

## Key facts

- **NCT ID:** NCT02161237
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-26
- **Primary completion:** 2016-12-22
- **Final completion:** 2016-12-22
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161237, "Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02161237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*